Financial Review: Eloxx Pharmaceuticals (ELOX) versus Its Competitors

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its valuation, analyst recommendations, earnings, risk, profitability, institutional ownership and dividends.

Profitability

This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.38%	-223.56%	-16.98%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eloxx Pharmaceuticals and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7612	13663	25497	1003	2.42

Eloxx Pharmaceuticals currently has a consensus target price of $38.33, suggesting a potential upside of 161.84%. As a group, “Pharmaceuticals” companies have a potential upside of 28.24%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than its rivals.

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.09, suggesting that their average share price is 409% less volatile than the S&P 500.

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-9.51
Eloxx Pharmaceuticals Competitors	$3.50 billion	$3.13 billion	547.44

Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Eloxx Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.